FDA Approved New Therapy for Sanfilippo Syndrome Type A
The treatment is for children aged 2 to 5 years diagnosed with this rare genetic condition.
Updated on Sept. 18, 2026 in Allergies
The FDA approved Fayuvi to treat Sanfilippo syndrome type A, a rare genetic disorder affecting one in every 50,000 to 200,000 people. The new therapy is available for young children who currently face a life expectancy of 11 to 19 years.
Why it matters
Patients with this condition lack the sulfamidase enzyme, causing a harmful accumulation of heparan sulfate in the body and brain. This approval offers a new option for children with type A, which accounts for more than half of all cases.
In a clinical study of children aged 2 to 5 years, participants maintained or improved cognitive function following treatment. This finding is preliminary, as the study population was narrow and results require long-term observation.
The players
FDA
The federal agency responsible for regulating pharmaceuticals and medical devices in the United States.
The details
Fayuvi utilizes an adeno-associated virus serotype 9 to deliver a working copy of the SGSH gene directly into the patient's cells. To manage the treatment, patients receive a single intravenous dose administered alongside a corticosteroid regimen that continues for 8 weeks post-infusion. Potential risks include tumor development and thrombotic microangiopathy, while common side effects involve nausea, vomiting, fever, and decreased blood cell counts.
Timeline
- 2026-09-18
FDA approved Fayuvi for children with Sanfilippo syndrome type A.
1 to 4 years of age: Typical onset of symptoms for Type A patients.
2 to 5 years of age: Age range of participants in the clinical study.
8 weeks: Required minimum duration for post-infusion corticosteroid treatment.
11 to 19 years: Standard life expectancy for individuals with Type A.
Health Landscape
This approval follows the established precedent of the FDA Orphan Drug designation program for expediting treatments for rare genetic conditions. It marks a shift toward gene-delivery mechanisms for metabolic disorders that previously lacked targeted interventions.
Families affected by this diagnosis should discuss the safety profile and eligibility criteria for this new gene therapy with their specialist. Monitoring for potential side effects such as changes in blood cell counts or liver enzymes remains a critical part of post-treatment care.
The takeaway
Sanfilippo syndrome type A is a progressive condition requiring early clinical management. If a child shows signs of developmental regression, consult a metabolic specialist about current testing and available therapeutic options.
Further reading
For broader information on managing rare conditions, see our Allergies section.
